GlassScriptPhysician profile
Erik O Esper
NPI 1093796625
$3,219.23
in general payments reported to CMS, 2019-2025
24 companies · $343 in 2025
The $343 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,061 · 2020: $362 · 2021: $373 · 2022: $358 · 2023: $407 · 2024: $316 · 2025: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,066.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,065.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $576.01 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $307.13 | 2019-2025 | Wegovy, Ozempic, Saxenda |
| Janssen Pharmaceuticals, INC | $287.68 | 2019-2022 | |
| Lilly USA, LLC | $250.39 | 2019-2023 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $233.73 | 2019-2025 | Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.68 | 2019-2023 | Jardiance, Synjardy |
| Pfizer INC. | $203.32 | 2019-2025 | |
| Glaxosmithkline, LLC. | $149.43 | 2019-2023 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $146.16 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $115.03 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $96.69 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.47 | 2019-2020 | |
| Allergan, INC. | $87.33 | 2019-2020 | |
| Amgen INC. | $77.16 | 2019-2023 | Otezla, Repatha |
| Abbvie INC. | $71.80 | 2021-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $58.95 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $58.33 | 2019-2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $45.99 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.03 | 2019 | |
| Madrigal Pharmaceuticals | $31.80 | 2025 | Rezdiffra |
| Sumitomo Pharma America, INC. | $26.70 | 2024 | Myfembree |
| Alkermes, INC. | $20.92 | 2025 | Vivitrol |
| Xeris Pharmaceuticals, INC. | $11.43 | 2020 | |
| Corcept Therapeutics | $11.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erik Esper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.